Back to today’s briefing

Story perspectives

U.S. Obesity Rate Drops: Are GLP-1 Drugs the Key?

11/2/2025

40 5

Summary

Story summary

Gallup data show U.S. obesity declined from 39.9% in 2022 to 37% in 2025.
The decline may reflect increased use of GLP-1 drugs such as Ozempic and Wegovy.
They suppress hunger and improve insulin signaling, but weight loss requires ongoing use.
Critics say obesity should be addressed through healthier food and exercise.
Still, the environment may promote weight gain, leaving GLP-1 drugs as a crucial tool.

1 of 1

Story summary

Gallup data show U.S. obesity declined from 39.9% in 2022 to 37% in 2025.
The decline may reflect increased use of GLP-1 drugs such as Ozempic and Wegovy.
They suppress hunger and improve insulin signaling, but weight loss requires ongoing use.
Critics say obesity should be addressed through healthier food and exercise.
Still, the environment may promote weight gain, leaving GLP-1 drugs as a crucial tool.